This brief review focuses on the transcriptional regulation of liver carnitine palmitoyltransferase I (L-CPT I) by pancreatic and thyroid hormones and by long-chain fatty acids (LCFA). Both glucagon and 3,3',5-tri-iodothyronine (T,) enhanced the transcription of the gene encoding L-C P T I, whereas insulin had the opposite effect.
Introduction
Long-chain fatty acids (LCFA) have an essential role as an energy source for many tissues of the organism, especially the heart and skeletal muscles. In these tissues, LCFA are oxidized into the mitochondria by /I-oxidation to provide ATP. In the liver, LCFA have an additional role. The acetyl-CoA generated by P-oxidation can be used for the production of ketone bodies (acetoacetate and 8-hydroxybutyrate), which are released into the circulation for further use as alternative fuels for extrahepatic organs, especially the brain. In adult mammals, ketogenesis occurs mainly in the liver, in response to fasting, diabetes and prolonged exercise. In suckling rats, ketogenesis also occurs in the intestine and to a smaller extent in the kidney (reviewed in [l]). In mammalian liver, fatty acid oxidation occurs in both mitochondria and peroxisomes. During the past decade the role of peroxisomes received considerable attention since the discovery that hypolipidaemic drugs induce peroxisomal proliferation in rodents and after the characterization of related human diseases [2]. However, the contribution of peroxisoma1 B-oxidation represents only 10-1 5 yo of total ,&oxidation in the neonatal rat liver [3, 4] .
Hepatic fatty acid oxidation involves four specific steps (Scheme 1) : (1) uptake and activation of fatty acids into fatty acyl-CoA, (2) translocation of fatty acyl-CoA into the mitochondria, (3) /%oxidation of fatty acyl-CoA and (4) ketone body production. The capacity for long-chain fatty acid oxidation is very low in fetal tissues and it increases markedly during the neonatal period (reviewed in
[l]). The postnatal development of liver mitochondrial LCFA oxidation and ketogenesis is closely related to the appearance of the carnitine palmitoyltransferase (CPT) system. The C P T system allows the transfer of LCFA inside the mitochondria and is composed of three distinct entities: C P T I, localized in the outer mitochondrial membrane; carnitine-acylcarnitine translocase; and C P T 11, localized on the inner mitochondria1 membrane (reviewed in [S]). It is generally accepted that the oxidation of LCFA is regulated at the level of C P T I through different mechanisms: (1) changes in C P T I activity, (2) changes in the concentration of malonyl-CoA (a physiological inhibitor of this enzyme), and (3) changes in the sensitivity of C P T I to malonylCoA inhibition.
In the rat, profound nutritional and hormonal modifications occur immediately after birth (reviewed in [l]). The high-carbohydrate/low-fat diet of the fetus is abruptly replaced by a high-fat/low-carbohydrate diet (milk). This dramatic change in nutrition increases plasma glucagon and decreases plasma insulin, and there is a gradual increase in the concentration of plasma thyroid hormones (reviewed in [l]). Under these conditions, there is a marked increase in C P T I gene transcription, an accumulation of C P T I mRNA and the synthesis of C P T I protein (reviewed in [l] ). These results suggest that the regulation of C P T I gene expression is dependent on hormonal and/or nutritional factors.
T h e aim of the present review is to discuss recent advances in the understanding of L-CPT I gene expression, with emphasis on the possible mechanisms by which LCFA and hormones mediate their effects on gene transcription.
Regulation of L-CPT I gene expression by hormones
T h e regulation of specific gene expression in response to changes in the hormonal environment has become a major aspect of modern biology.
Here we briefly review the role of insulin, glucagon and thyroid hormones in the regulation of L-CPT I gene expression.
Very few studies have been performed to address the question of direct effects of hormones on the regulation of L-CPT I gene expression in vitro with cultured hepatocytes or hepatoma cells. Recent studies in our laboratory have shown that the addition of glucagon or dibutyryl CAMP to cultured fetal hepatocytes increased the concentration of L-CPT I mRNAs in a dose-dependent 
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Step 3 FStep . In cultured fetal rat hepatocytes, insulin antagonized the CAMP-induced accumulation of C P T I mRNA [6] . Insulin also decreased L-CPT I mRNA in H4IIE rat hepatoma cells without affecting the half-life of its mRNA [7] . By contrast, neither CAMP nor insulin affects C P T I1 gene expression [6] . This marked difference in gene regulation by pancreatic hormones was probably due to differences in the promoter structure of these two genes.
There was no CCAAT-enhancer-binding protein a or CAMP-response-element-binding protein ( [lo] ). The consensus sequence of T R E contains a direct repeat of two AGGTCA motifs separated by four nucleotides (DR4). T R binds to DNA as a heterodimer with the retinoid X receptor (RXR). Two isoforms of T R are known: T R a and TR/? [ l l ] . In the liver, the TR/? isoform seems to mediate many of the effects of T,. T h e induction of several hepatic genes (S14 and malic enzyme) in response to T, is suppressed in TR/? knock-out mice [12] . Recently, it has been shown that L-C P T I promoter contains a functional T R E located at approx. -3 kb from the cap site of the gene [13] . Studies of DNA-protein binding reveal that TR/? binds this element as a heterodimer with RXRa. This interaction is not sufficient to obtain maximal induction of the gene encoding C P T I in response to T,. Co-operation with a sequence located in the first intron of the gene encoding C P T I is required [13] . Similar results have been reported for other hepatic genes such as those for glutamine synthase [ 141 and the very-low-density apolipoprotein I1 (apoVLDLI1) [15] .
Regulation of L-CPT I gene expression by LCFA
LCFA are important nutrients for growth and development. Apart from their role in membrane structure, metabolism and signal transduction, it has become increasingly clear that they have also a role in the expression of a number of genes encoding enzymes involved in carbohydrate metabolism and lipid metabolism. Here we focus our discussion on the most recent reports on the effects of LCFA on L-CPT I gene expression.
In the liver, the expression of a number of genes is stimulated by LCFA in a physiologically relevant manner. LCFA caused a marked increase in the specific C P T I mRNA level in primary culture of fetal rat hepatocytes [6] . This accumulation, which is time-and dose-dependent, results from two mechanisms: (1) T h e inhibitory effect of LCFA on hepatic lipogenic gene expression seems to be restricted to polyunsaturated fatty acids (PUFA) (reviewed in [19] ). In contrast, the stimulatory effect of LCFA on L-CPT I gene expression is independent of the degree of saturation of LCFA [6] . A similar phenomena has been reported for the genes encoding liver fatty-acid-binding protein [20] , medium-chain acyl-CoA dehydrogenase [21] and mitochondrial 3-hydroxymethylglutaryl-CoA synthase [22] . Interestingly, the gene encoding L-C P T I is also induced by LCFA in a pancreatic /?-cell line I N S 1 [23] .
Are the effects of LCFA on gene transcription mediated by a metabolite?
T h e nature of the metabolite(s) triggering the transcriptional effect of LCFA in mammals is still controversial. For example, recent studies suggested that mitochondrial oxidation of LCFA is required to exert their inhibitory effect on gene expression in rat pancreatic /?-cells [24] . In contrast, several studies have shown that when the oxidation of LCFA is blocked by specific inhibitors (tetradecylglycidic acid) or by a non-metabolizable analogue of fatty acids (2-bromopalmitate), the stimulation of LCFA on gene expression is still present. This was clearly demonstrated for aP2 [25] , liver C P T I [6], longchain fatty acyl-CoA synthase (ACS) [26] and liver-type fatty-acid-binding protein in distal ileum [27] . This suggested that the effects could be mediated by LCFA itself or by their CoA derivatives. The role of long-chain fatty acyl-CoA in the regulation of gene transcription has been clearly established in bacteria (reviewed in [28] ). AcylCoAs are also active in modulating gene transcription in yeast (reviewed in [28] ). However, there is no clear demonstration of the role of LCFA or their corresponding CoA esters as modulators of gene expression in higher eukaryotes. Indirect evidence suggests that LCFA rather than their acyl-CoA esters could be active components in gene expression: (1) in COS-7 cells transfected with the peroxisomal acyl-CoA oxidase promoter linked to the chloramphenicol acetyltransferase reporter gene, the transcription was increased more efficiently by free arachidonic acid than by arachidonyl-CoA [29] ; (2) in an adipocyte cell line, the induction of aP2 gene transcription by LCFA occurred before the expression of the gene encoding ACS [30] ; (3) in the Fao hepatoma cell line, the stimulation of C P T I gene expression by LCFA was maintained even in the presence of ACS inhibitors [31, 32] . These experiments, with chimaeric gene transfection, metabolic inhibitors and assays in vitro, provide only indirect evidence and it is clear that additional experiments will be required before it can be concluded that LCFA, and not their acyl-CoA derivatives or other metabolites, are the active modulators of gene transcription.
Contribution of nuclear receptors to LCFAinduced gene expression
T h e molecular mechanisms by which LCFA or their metabolites regulate gene transcription are still unclear in mammalian cells. On the basis of the comparison between the effects of LCFA and the peroxisome proliferator, it was suggested that LCFA could mediate gene transcription through the activation of nuclear receptors of the steroidthyroid superfamily, the peroxisome-proliferatoractivated receptor (PPAR) (reviewed in [33] ). Several mechanisms have been proposed for PPAR activation by fatty acids : a ligand-mediated process, activation through binding to a cytosolic heat shock protein (HSP72) or activation secondary to a phosphorylation-mediated MAP (mitogen-activated protein) kinase (reviewed in [31, 34] ). The modulation of gene transcription is due to the binding of the heterodimer PPAR/RXR to a specific DNA sequence, the peroxisomeproliferator-responsive element (PPRE) (reviewed in [33] ). PPRE was initially defined as a direct repeat of two core recognition motifs AGGTCA spaced by one nucleotide (DR1) [35] . Further analyses have completed this first definition by adding the following properties: an imperfect core DR1, an adenine as the spacing nucleotide between the two hexamers, and an extended 5'-AACT sequence, which seems to be crucial for the polarity and for the selectivity of recognition (reviewed in [33, 36] ). This modulation is accomplished with the help of co-activator complexes that bind to the AF2 sequence located in helix 12 of the ligand-binding domain of the nuclear receptor (reviewed in [37, 38] ). In keeping with this, it has been shown that LCFA stimulated the transcription of a DNA construct consisting of the gene promoter for human muscle C P T I (-1025 bp to -12 bp from the cap site) linked to a luciferase reporter gene in transfected HepG2 hepatoma cells [39] . However, this stimulation by LCFA required the co-transfection of a PPARa construct, so it is questionnable whether the overexpression of nuclear receptors reflect a physiologically relevant process. In fact, if the transcriptional effect of LCFA was due to the synthesis of a putative ligand of PPARa, it is difficult to understand why the induction of the muscle C P T I-luciferase chimaeric gene in response to LCFA did not occur with endogenous PPARa. The role of PPAR in mediating transcriptional effects of LCFA is still a matter of controversy. For instance, it was shown that the repression of hepatic Spot 14 gene transcription (a gene encoding a lipogenic-like enzyme) by PUFA was not mediated though the activation of PPARa [40] . This was confirmed recently with a PPARanull mouse in which the induction of peroxisomal /I-oxidation genes by PUFA was blunted, whereas inhibition of the expression of the gene encoding spot 14, fatty acid synthase or L-pyruvate kinase normally occurred [41, 42] . Several experimental results obtained in cultured fetal rat hepatocytes suggest that the effects of LCFA on L-CPT I gene transcription are mediated by a pathway different from that of peroxisome proliferators (Figure 1) . First, LCFA induce the gene expression of C P T I but not C P T 11, whereas clofibrate (a peroxisome proliferator) enhances the concentration of both C P T I and C P T I1 mRNA [6]. Secondly, the LCFA-induced accumulation of C P T I mRNA is inhibited by insulin, whereas the clofibrate-induced expression of the C P T I and I1 genes is not [6] (Figure 1) .
Thirdly, the starvation-induced expression of the gene encoding C P T I is maintained in the liver of PPARa-null mice [4345]. As the expression of this gene is regulated both by LCFA and by the changes in pancreatic hormones [6], its induction during starvation is probably due to the decrease in plasma insulin levels and the rise in plasma glucagon levels. Thus the stimulation of the gene encoding L-CPT I by LCFA seems to be a PPARa-independent mechanism. This was confirmed in cultured hepatocytes from PPARa-null mice in which the absence of LCFA-induced L-C P T I gene expression was not due to the absence of PPARa receptor but to an intrinsic defect of response to LCFA because they also failed to stimulate L-CPT I gene expression in wild-type mice [32] . Such a dissociation between the transcriptional effects of LCFA or peroxisome proliferators has already been observed for other genes. ApoA-I1 [lS] and FAT-CD36 genes contain a PPRE but do not respond to LCFA (reviewed in [36] ). Moreover, PUFA inhibit the transcription of the AS and A6 desaturases [46, 47] , whereas the same genes are stimulated by peroxisome proliferators.
T o investigate further the molecular mechanisms involved in the regulation of L-CPT I gene expression by LCFA and peroxisome proliferators, we performed transient transfection of plasmids containing different sequences of the L-C P T I promoter into cultured hepatocytes and hepatoma cells. The results confirm that clofibrate stimulates L-CPT I through a classical DRl motif (PPRE), whereas LCFA induce L-CPT I via elements localized in the first intron of the gene [32] (Figure 2 ). With the use of gel-shift experiments we have shown that the nuclear receptor complex PPARa-RXRa binds to the L-CPT I-PPRE sequence [32] . PPARa alone was unable to bind to this sequence, indicating that heterodimerization with RXRa is necessary for DNA binding [48] . Previous experiments have shown that distinct sequences were responsible for the effects of peroxisome proliferators and PUFA on the hepatic promoter of the Spot 14 gene [40, 41] . Similarly, the PUFA-induced suppression of the transcription of the gene encoding L-type pyruvate kinase did not require the presence of PPARa. The heterodimer PPARa-RXRa did not bind the PUFA-responsive element sequence of the L-type pyruvate kinase promoter [42] . Finally, our results demonstrate that LCFA can up-regulate gene expression through PPARa-independent pathways and suggest that the regulation of hepatic gene expression by dietary lipids is more complex than previously suggested. Further studies will be necessary to identify the LCFA response element (FARE) and the protein and co-activators involved in the activation of genes in response to LCFA.
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Conclusions
This brief review has underlined the notion that peroxisome proliferators and LCFA can mediate gene transcription (at least for L-CPT I) by distinct mechanisms. This indicates that, for a given gene, its potential for control by LCFA does not necessarily result from the presence of a putative PPRE consensus sequence in the regulatory region of the gene. Moreover, this review has also underlined the importance of the first intron of L-CPT I gene for effects mediated by LCFA and by thyroid hormone.
